Clinical Sciences Department, California State University, Dominguez Hills, Carson, CA, USA.
J Hosp Infect. 2020 Jan;104(1):4-11. doi: 10.1016/j.jhin.2019.09.021. Epub 2019 Oct 4.
Acinetobacter baumannii infections have become an emerging health concern in hospitals across the world and are often associated with nosocomial infections with poorer clinical outcomes in patients with prolonged hospital stay. Management of infections involves prompt identification of the infecting strain, isolating the source of infection, and proper choice of antibiotic regimen. However, resistance to first-line antimicrobial drugs, combined with a lack of equally effective alternatives, complicates the treatment of multidrug-resistant A. baumannii. Presently, multidrug-resistant A. baumannii is a serious health concern in hospitals and long-term care facilities and requires immediate and sustained prevention efforts to control the rate of incidence. This review describes trends in epidemiology, genetic markers, and other factors that influence the incidence of multidrug-resistant A. baumannii. Current and emerging treatments as well as infection control strategies are discussed.
鲍曼不动杆菌感染已成为全球医院面临的一个新的健康问题，常与医院获得性感染相关，导致住院时间延长的患者临床结局更差。感染的管理包括及时识别感染株、隔离感染源和选择适当的抗生素治疗方案。然而，对一线抗菌药物的耐药性，加上缺乏同样有效的替代药物，使得治疗多重耐药鲍曼不动杆菌变得复杂。目前，多重耐药鲍曼不动杆菌是医院和长期护理机构的严重健康问题，需要立即采取持续的预防措施来控制发病率。本综述描述了流行病学、遗传标记物和其他影响多重耐药鲍曼不动杆菌发病率的因素的趋势。讨论了现有的和新兴的治疗方法以及感染控制策略。
